Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (2702)	10/21/2000 9:28:00 PM
From: Sir Auric Goldfinger	Read Replies (1) \| Respond to of 5582

paed.uscourts.gov

To: DanZ who wrote (2702)	10/21/2000 9:40:16 PM
From: Sir Auric Goldfinger	Respond to of 5582

Seems pretty recent to me. BTW, nice scumbag broker: "GUNNALLEN FINANCIAL REITERATES BUY RATING ON GUMTECH INTERNATIONAL WITH Story Filed: Thursday, January 28, 1999 01:39 PM EST 12-Month Price Target of $24 TAMPA, Fla., Jan. 28 /PRNewswire/ -- The following is being issued by GunnAllen Financial, a member of the National Association of Securities Dealers, CRD number 17609: Phoenix, AZ-based GumTech International (Nasdaq: GUMM) develops, markets, and distributes specialty chewing gum products under its own label, on a private-label basis, and for household-name confectionery companies, including BreathAsure Dental Gum and AcuTrim Diet Gum. The gums are designed to provide functional health benefits to consumers, and are manufactured in the only stainless steel gum manufacturing facility registered with the U.S. Food and Drug Administration to produce over-the counter drug containing products. GumTech today announced the formation of an LLC to jointly develop and market ZICAM, a homeopathic nasal gel designed to substantially reduce the duration of the symptoms of the common cold. At any one time, nearly one-third of all Americans had a cold in the previous two weeks. In addition, children have about six to eight colds per year, with some children suffering from as many as 12 in a one-year period. The science behind ZICAM can be found at the ZICAM website: www.zicam.com. Expenditures on OTC remedies for this ailment approximate $1.5 billion in the U.S alone. GunnAllen believes that ZICAM offers tremendous upside potential to its current FY1999 revenue forecast of $23 million, and may add as much as $0.30 per share to its FY1999 estimate of $0.47 per diluted share. GunnAllen Financial continues to believe in the GumTech story independent of ZICAM. The functional chewing gum market is growing rapidly as evidenced by the number of new products hitting store shelves. In addition to dental gum, GunnAllen believes there is still room in the diet sector. Furthermore, with the February 9, 1999 expiration of the new product exclusivity period for SmithKline Beecham Consumer Healthcare's Nicorette Gum under the Waxman-Hatch Act, a huge market for private label and branded nicotine-containing gums appears evident. GunnAllen is reiterating their buy rating on GumTech with a twelve-month price target of $24. SOURCE GunnAllen Financial 01/28/99 CONTACT: David Rich of GunnAllen Financial, 800-713-4046, ext. 234 or drich@gunnallen.com "